New research for the possible treatment for inflammatory arthritis

Nov, 2021 - by CMI


The Schroeder Arthritis Institute researchers in Canada have conducted experiments that could result in new therapies for axial spondylarthritis (SpA), a debilitating condition type of arthritis that impacts 1-2 % of people in Canada and leads to inflammation in the joints, spine, eyes, skin, and gut.

The research focuses on the effect of Macrophage migration inhibitory factor (MIF), a protein that causes the body to respond to inflammation or immunological stimulus. The involvement of MIF in the development of SpA disease remained unclear till recently. The activity of MIF and its receptor CD74 was found to be higher in the tissues and blood of pre-clinical models in this research. Human neutrophils (a kind of white blood cell that triggers the body immunity) from patients with SpA produced greater levels of MIF than healthy people, according to the researchers. As a result, additional cells begin to produce greater inflammation.

The content or expression of MIF in the blood, joint fluids, and gut tissues of SpA patients is much higher than in the gut tissues, blood, and joint fluids of other types of healthy individuals or arthritis patients, according to a 2017 study. They also established that MIF may be involved in the growth of new bone formation in the same publication. These discoveries have served to confirm earlier findings and expand understanding of MIF's function in SpA. In a pre-clinical model, MIF098, a selective MIF blocker, successfully prevented and limited the onset and progression of SpA. Stiffness, Inflammation, and discomfort are common symptoms of SpA, which can progress to spinal fusion and reduced mobility throughout time. But it's not just the disease that these people should be concerned about; they have a 60% higher probability of having a stroke and a 30% higher chance of having cardiovascular diseases or having a mental disorder than the general public.

Clinical studies will be used to evaluate the ability of MIF blockers in SpA patients, to regulate the appropriate concentration and frequency of MIF-targeted medicines for humans, and study probable adverse effects to guarantee safety.